SCHEMBL22617536

SCHEMBL22617536

O=C(O)c1nnc(-c2ncccc2F)s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.42
TDP1 Q9NUW8 1/20 0.42
NAPRT Q6XQN6 2/20 0.40
FAAH O00519 1/20 0.36
CES1 P23141 1/20 0.36
NPC1 O15118 4/20 0.36
RAB9A P51151 4/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
P2RY1 P47900 1/20 0.35
TRPV1 Q8NER1 1/20 0.34
ALDH1A1 P00352 2/20 0.34
ALB P02768 1/20 0.34
CYP3A4 P08684 1/20 0.34
MAPT P10636 1/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34
BLM P54132 1/20 0.34
AGER Q15109 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22617517 0.82 KDM4E (0.42) KDM4ETDP1NAPRTFAAHCES1
SCHEMBL22617535 0.80 P2RY1 (0.43) KDM4ENPC1RAB9ASMN1; SMN2P2RY1
SCHEMBL8840237 0.78 TTR (0.43) KDM4ECES1NPC1RAB9ASMN1; SMN2
SCHEMBL8840310 0.78 KDM4E (0.54) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL27164857 0.77 KDM4E (0.43) KDM4ETDP1NAPRTCES1SMN1; SMN2
SCHEMBL30799197 0.77 KDM4E (0.43) KDM4ETDP1NAPRTCES1SMN1; SMN2
SCHEMBL12571310 0.77 TERT (0.43) KDM4ETDP1NAPRTFAAHCES1
SCHEMBL17101564 0.74 KDM4E (0.59) KDM4ESMN1; SMN2ALDH1A1LMNAHPGD
SCHEMBL12571312 0.73 KDM4E (0.65) KDM4EFAAHCES1NPC1RAB9A
SCHEMBL14801613 0.72 PIM1 (0.46) KDM4ETDP1NAPRTALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3388428-B1 FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR SUZHOU SINOVENT PHARMACEUTICALS COMPANY (CN) 2021-08-04 EP disclosed
US-10821104-B2 Five-membered heterocyclic amides WNT pathway inhibitor Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) 2020-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10821104-B2 Five-membered heterocyclic amides WNT pathway inhibitor WNT1, WNT3, WNT3A KDM4E 1435/4885TDP1 4878/4885NAPRT 1055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.